In an unexpected discovery, UCLA researchers have found that a gene previously known to control human metabolism also controls the equilibrium of bone and fat in bone marrow as well as how an adult stem cell expresses its final cell type.

University of Illinois researchers have developed a molecular probe that seeks out these elusive cells and lights them up so they can be identified, tracked and studied not only in cell cultures, but in their native environment: the body.

A clinical trial has begun which will use stem cell transplants to grow a new immune system for people with untreatable Crohn's disease -- a painful and chronic intestinal disease which affects at least 115,000 people in the UK

People with multiple sclerosis sometimes become desperate and will travel to other countries for experimental stem cell treatments. That?s not always a good idea.

The discovery by Stanford scientists drills a peephole into the black box of cellular reprogramming and may lead to new ways to generate induced pluripotent stem cells in the laboratory.

A new genetic study found another explanation, Yale University researchers report July 5 in the journal Neuron.

A team from the University of California, San Francisco, devised a new electroporation-based CRISPR-Cas9 method, eliminating viruses from the gene editing process and laying the groundwork for safer, more precise and more efficient editing for CAR-T cancer treatments and other cell therapies.

In a 10-patient cohort study led by Dr. Jean Roy, hematologist and professor at the Faculty of Medicine of Université de Montréal, that aims to understand how to mitigate the risks associated with the treatment of multiple myeloma, a malignant cancer, researchers have adopted an innovative approach based on the unique immunological properties of umbilical cord blood in an effort to improve the safety and efficiency of allografting, the preferred treatment for this disease.

The FDA approved an investigational new drug application from Cellectis for a Phase 1 clinical trial of UCART22, its third gene-edited CAR-T cell candidate.

Christiana Care has been talking with the U.S. Food & Drug Administration about developing a gene editing tool called CRISPR to assist in lung cancer treatments. One question they?ll face in the future is if insurance companies will pick up the cost.